MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Could This Be the First Malaria Vaccine?
US News & World Report features a story on Sanaria's new finding that our experimental vaccine against malaria has provided protection for some against the illness for more than a year.
Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Clinical Trial
Results of a clinical trial of Sanaria® PfSPZ (Plasmodium falciparum sporozoite) Vaccine to prevent malaria infections, published today in the online issue of Nature Medicine magazine, show that the vaccine provided protection against infection with malaria parasites for at least 14 months in subjects who were exposed to Plasmodium falciparum parasites. The findings put the Sanaria vaccine on track to be the first malaria vaccine providing durable protection against infection with malaria parasites. Plasmodium falciparum is the malaria parasite that causes about 438,000 deaths and 214 million cases annually.
Sanaria Earns ‘Bioscience Company Of The Year’ Award
The Montgomery County Small Business Awards were announced June 24 and the winner of the "Bioscience Company of the Year" is Sanaria, Inc.
Government Of Equatorial Guinea And Oil Companies Agree To $48.5 Million Funding Of Malaria Vaccine Development Program With Sanaria Inc.
The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria® PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018.
Dr. Stephen L. Hoffman wins 2015 CEO of the year at the World Vaccine Congress, Vaccine Industry Excellence Awards
Announced at the award ceremony during the 15th World Vaccine Congress, the 8th Vaccine Industry Excellence (ViE) Awards recognise those who have done outstanding work in the field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of vaccines in the last year.
Sanaria’s Executive VP of Manufacturing and Process Development, Dr. B. Kim Lee Sim, featured in Malaymail
At a recent photoshoot by legendary photographer Annie Leibovitz of prominent scientists honoured by the Bill & Melinda Gates Foundation, one woman stood out from the rest. Dr Betty Sim Kim Lee is the president and leading researcher of an organisation working on the development of vaccines for infectious diseases. She is also a Malaysian, a proud Nyonya born and bred in Kota Bharu. So, how did this small town girl become one of the most important malaria fighters in the world today?
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.